This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Coproxamol

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is dextropropoxythene and paracetamol (in a combination of 32.5 mg of dextroproxyphene with 325mg of paracetamol).

  • dextropropoxyphene is well absorbed and metabolised in the liver. It has a half-life of 12 hours
  • dextropropoxyphene does not commonly causes adverse effects in short courses of therapeutic doses. Note though that chronic usage may cause constipation and overdose may cause similar effects to morphine
  • there is no evidence that dextropopoxythene 62.5 mg or 100 mg in combination with paracetamol 650 mg, given as a single dose, is more effective than paracetamol 650 mg given alone in the relief of ACUTE pain e.g. after episiotomy, tooth extraction, orthopaedic surgery (2)
  • there is no robust evidence that co-proxamol is any more effective than full strength paracetamol in the management of chronic pain (3)
  • problems of coproxamol in overdose (2)
    • in 2004 it was reported that, in England and Wales, between 300 and 400 people die each year following deliberate or accidental overdose with co-proxamol (Distalgesic; Cosalgesic; Dolgesic), a fixed-dose combination of paracetamol (325mg) and dextropropoxyphene (32.5mg) indicated for the treatment of mild to moderate pain
    • combination with alcohol or CNS depressants particularly hazardous and may cause fatal apnoea or cardiac arrhythmia

Check the summary of product characteristics before prescribing this drug.

Reference:

  1. Drug and Therapeutics Bulletin (1998); 36 (10): 80
  2. Current Problems in Pharmacovigilance (2004); 30:1-12.
  3. MeReC Bulletin (2006);16 (4):13-16.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.